Pharmacoeconomic review report (resubmission): Nusinersen (Spinraza) (Biogen Canada Inc.) indication : treatment of patients with 5q spinal muscular atrophy
Those with SMA type II achieve the milestone of sitting unsupported, but never walk independently; symptoms generally appear between six and 18 months after birth and most patients will survive past the age of 25, with life expectancy improved by aggressive supportive care. SMA type III makes up app...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
April 2019, 2019
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references